1. Home
  2. NYAX vs MESO Comparison

NYAX vs MESO Comparison

Compare NYAX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nayax Ltd.

NYAX

Nayax Ltd.

HOLD

Current Price

$71.77

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.74

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYAX
MESO
Founded
2005
2004
Country
Israel
Australia
Employees
N/A
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NYAX
MESO
Price
$71.77
$15.74
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$49.50
N/A
AVG Volume (30 Days)
24.4K
188.2K
Earning Date
05-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.66
$629.74
Revenue Next Year
$21.70
$30.65
P/E Ratio
$89.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.50
$9.88
52 Week High
$70.50
$21.50

Technical Indicators

Market Signals
Indicator
NYAX
MESO
Relative Strength Index (RSI) 74.59 53.18
Support Level $42.74 $15.62
Resistance Level N/A $16.37
Average True Range (ATR) 1.55 0.37
MACD 0.73 0.02
Stochastic Oscillator 98.01 53.52

Price Performance

Historical Comparison
NYAX
MESO

About NYAX Nayax Ltd.

Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: